Trial Profile
A Phase 3, randomized, double-blind, placebo-controlled multi-center study of RAD001 in combination with letrozole (Femara) to investigate the value of adding RAD001 to letrozole as a first-line therapy in postmenopausal women with advanced breast cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Mar 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Letrozole
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 07 Mar 2016 New trial record